Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD16A | O95870 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 4/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048013 | 0.88 | ABHD16A (0.65) | ABHD16AALDH1A1LMNAMGLLFAAH | |
| SCHEMBL7040780 | 0.86 | ABHD16A (0.63) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL2853190 | 0.84 | ABHD16A (0.49) | ABHD16AALDH1A1LMNAMGLLSIRT6 | |
| SCHEMBL7043172 | 0.83 | ABHD16A (0.57) | ABHD16AMGLLFAAHMAPTLIPC | |
| SCHEMBL2237968 | 0.80 | ABHD16A (0.72) | ABHD16AALDH1A1LMNAMGLLFAAH | |
| SCHEMBL4404667 | 0.79 | ABHD16A (0.59) | ABHD16AALDH1A1MGLLFAAHLPL | |
| Hydrochloric Acid SCHEMBL5425491 | 0.78 | ABHD16A (0.58) | ABHD16AALDH1A1MGLLFAAHLPL | |
| SCHEMBL2855611 | 0.76 | ABHD16A (0.50) | ABHD16AMGLLFAAH | |
| SCHEMBL2853363 | 0.75 | ABHD16A (0.44) | ABHD16AMGLLTDP1 | |
| SCHEMBL2235103 | 0.72 | ABHD16A (0.74) | ABHD16AALDH1A1MGLLFAAHLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138414-B2 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| EP-1523475-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SLC5A2, CYP1A2, HBB | ABHD16A 3526/4885ALDH1A1 435/4885LMNA 3448/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | ABHD16A 3430/4885ALDH1A1 259/4885LMNA 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.